Afamelanotide (Scenesse): The FDA-Approved Melanocortin Peptide — and How It Differs From Grey-Market Melanotan

AI generatedcosmeticfda-approved
This article was AI-generated for informational purposes only. It is not medical advice. Always verify claims with the cited sources.

Most of the melanocortin peptides discussed online live in a regulatory grey zone. Afamelanotide is the rare exception: it is an FDA-approved drug. But its story is unusually tangled, because the approved medicine and the "tanning peptide" sold in vials online are, chemically, the same molecule. Untangling that is the point of this log entry.

What afamelanotide is

Afamelanotide is a synthetic tridecapeptide — a structural analog of alpha-melanocyte stimulating hormone (alpha-MSH). It acts as a melanocortin-1 receptor (MC1R) agonist, driving melanogenesis in the skin. Practically, it increases production of eumelanin (the darker, more photoprotective pigment) independently of exposure to sunlight or artificial UV. That UV-independent pigmentation is the mechanism that makes it useful medically — and the same mechanism that made it attractive as a tanning shortcut.

Here is the fact that trips people up: afamelanotide was originally named melanotan (or melanotan-I / CUV1647). The melanotan-1 in a grey-market vial and the afamelanotide in an approved implant trace to the same peptide, first researched at the University of Arizona. The compound is not the whole story — the form, dose, sourcing, and oversight are.

The approved product: Scenesse

On October 8, 2019, the FDA approved SCENESSE (afamelanotide), developed by the Australian company Clinuvel, to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). EPP is a rare genetic disorder in which sunlight triggers severe, painful phototoxic reactions. Before Scenesse, there were no FDA-approved treatments to help these patients tolerate light — the FDA classed it as a first-in-class medication.

The approval rested on three trials totaling 244 adults, which measured pain-free hours in sunlight, outdoor hours under varying light conditions, and side effects. The approved product is not an injection you do at home. It is a single 16 mg implant inserted subcutaneously (above the anterior supra-iliac crest) by a trained provider, roughly every two months. Dosing, sourcing, sterility, and monitoring all sit inside a clinical system.

Even under that supervision, afamelanotide is not side-effect-free. In the approved-use data, the most common adverse events included nausea (about 31% of patients), injection-site reactions (about 22%), and headache (about 18%). The peptide itself has a short half-life (roughly 30 minutes); the implant format is what extends its effect. Because it increases pigmentation, dermatologic monitoring of moles and pigmented lesions is part of responsible use.

The grey-market version

Everything above describes a regulated drug for a rare disease. That is a world away from what is sold online as injectable "Melanotan 1" or "MT-1" powder for cosmetic tanning.

  • No legal status for human use. Tanning injections are not legal to buy for cosmetic use in the United States, and the FDA approval of afamelanotide for EPP does not validate off-label use at unregulated doses.
  • Unknown purity and dose. Powders sold online are not tested for purity, correct dosing, or sterility. A 2022 analysis of online-purchased alpha-MSH analog products found frequent contamination and outright compound misidentification — you often cannot know what is actually in the vial.
  • Documented safety signals. Dermatology bodies have flagged real harms. The Skin Cancer Foundation has noted case reports of melanoma developing after melanotan use, along with rapid changes in moles and pigmented lesions that can make skin-cancer detection harder. Reported adverse effects across melanotan use also include nausea and blood-pressure changes. Long-term effects remain largely unknown.

    • So the honest framing is not "afamelanotide good, melanotan bad." The molecule is shared. The difference is that Scenesse is a defined dose, in a sterile controlled-release implant, prescribed for a serious medical indication, with provider oversight and dermatologic monitoring — while the grey-market route strips away every one of those safeguards and adds contamination risk on top.

    Where this sits on the regulatory map

    It is worth being precise about scope. Afamelanotide is FDA-approved only for pain-free light exposure in adults with EPP. It is not approved as a tanning agent, a cosmetic, or a wellness peptide. That narrow indication is exactly why its approval says almost nothing about the safety of buying melanotan powder to tan. For how we categorize approved-vs-unapproved status across peptides, see our FDA status reference.

    For a research log, afamelanotide is a clean case study in a recurring theme: regulatory approval attaches to a product and an indication, not to a molecule in the abstract. The same peptide can be a carefully studied implant on one side of the line and an untested, contaminated, illegal injectable on the other.

    PepStash is a research log and reference tool. This article is educational and is not medical advice — it does not diagnose, treat, or recommend any protocol. Regulatory status and trial data change; always verify against primary sources and consult a licensed physician before making any decisions about your health.

    Not medical advice. For research purposes only. Consult a licensed physician before beginning any protocol.